D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 71 Citations 27,665 346 World Ranking 14973 National Ranking 7811

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Chemotherapy

His primary scientific interests are in Internal medicine, Oncology, Lung cancer, Cancer and Chemotherapy. His Internal medicine research incorporates elements of Gastroenterology and Surgery. His biological study spans a wide range of topics, including Cetuximab, Phases of clinical research, Carboplatin, Metastatic breast cancer and Survival analysis.

The Lung cancer study combines topics in areas such as Paclitaxel, Chemoradiotherapy, Radiation therapy and Epidermal growth factor receptor. The various areas that George R. Blumenschein examines in his Cancer study include Doxorubicin, Proportional hazards model and Pathology. His Chemotherapy study incorporates themes from Taxane, Pharmacotherapy and Disease.

His most cited work include:

  • Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck (1979 citations)
  • First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer (1127 citations)
  • Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study (1030 citations)

What are the main themes of his work throughout his whole career to date?

Internal medicine, Oncology, Lung cancer, Cancer and Chemotherapy are his primary areas of study. George R. Blumenschein has researched Internal medicine in several fields, including Gastroenterology and Surgery. The concepts of his Oncology study are interwoven with issues in Cetuximab, Nivolumab and Metastatic breast cancer.

His Nivolumab research incorporates elements of Clinical endpoint, Docetaxel and Head and neck. His Lung cancer study combines topics from a wide range of disciplines, such as Targeted therapy, Carcinoma, KRAS and Sorafenib. His work deals with themes such as Regimen, Metastasis, Radiation therapy and Immunotherapy, which intersect with Chemotherapy.

He most often published in these fields:

  • Internal medicine (74.24%)
  • Oncology (65.15%)
  • Lung cancer (20.96%)

What were the highlights of his more recent work (between 2015-2021)?

  • Internal medicine (74.24%)
  • Oncology (65.15%)
  • Nivolumab (8.33%)

In recent papers he was focusing on the following fields of study:

George R. Blumenschein focuses on Internal medicine, Oncology, Nivolumab, In patient and Lung cancer. His Internal medicine research focuses on Surgery and how it relates to Standard treatment. His research integrates issues of Cancer, Immunotherapy, Cetuximab, Phases of clinical research and Head and neck in his study of Oncology.

His Cetuximab study integrates concerns from other disciplines, such as Survival rate and Methotrexate. His Nivolumab research includes elements of Basal cell, Ipilimumab, Targeted therapy and Hazard ratio. His Lung cancer research is multidisciplinary, incorporating perspectives in Radiation therapy, Radiology, Carcinoma and Randomized controlled trial.

Between 2015 and 2021, his most popular works were:

  • Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck (1979 citations)
  • First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer (1127 citations)
  • Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study (432 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Chemotherapy

George R. Blumenschein mainly focuses on Internal medicine, Oncology, Nivolumab, Lung cancer and Clinical endpoint. In his study, which falls under the umbrella issue of Internal medicine, Standard treatment and Cancer is strongly linked to Surgery. His work investigates the relationship between Oncology and topics such as Cetuximab that intersect with problems in Survival rate.

George R. Blumenschein interconnects Major Pathologic Response, Head and neck squamous-cell carcinoma, Targeted therapy and Head and neck in the investigation of issues within Nivolumab. His studies in Lung cancer integrate themes in fields like Concordance and Chemoradiotherapy. George R. Blumenschein focuses mostly in the field of Clinical endpoint, narrowing it down to matters related to Survival analysis and, in some cases, Tumor progression.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Robert L. Ferris;George Blumenschein;Jerome Fayette;Joel Guigay.
The New England Journal of Medicine (2016)

2533 Citations

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study

Jeffrey D. Bradley;Rebecca Paulus;Ritsuko Komaki;Gregory Masters.
Lancet Oncology (2015)

1598 Citations

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

David P. Carbone;Martin Reck;Luis Paz-Ares;Benjamin Creelan.
The New England Journal of Medicine (2017)

1508 Citations

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.

Sewa S. Legha;Robert S. Benjamin;Bruce Mackay;Michael Ewer.
Annals of Internal Medicine (1982)

1013 Citations

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Lauren Averett Byers;Lixia Diao;Jing Wang;Pierre Saintigny.
Clinical Cancer Research (2013)

906 Citations

The BATTLE Trial: Personalizing Therapy for Lung Cancer

Edward S. Kim;Roy S. Herbst;Ignacio Ivan Wistuba;Jiun-Kae Jack Lee.
Cancer Discovery (2011)

881 Citations

Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer

Roy S. Herbst;David H. Johnson;Eric Mininberg;David P. Carbone.
Journal of Clinical Oncology (2005)

757 Citations

Leukocyte Interferon-Induced Tumor Regression in Human Metastatic Breast Cancer, Multiple Myeloma, and Malignant Lymphoma

Jordan U. Gutterman;George R. Blumenschein;Raymond Alexanian;Hwee-Yong Yap.
Annals of Internal Medicine (1980)

742 Citations

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

Daniel R Gomez;George R Blumenschein;J Jack Lee;Mike Hernandez.
Lancet Oncology (2016)

648 Citations

Pathological Assessment of Response to Induction Chemotherapy in Breast Cancer

Lorne D. Feldman;Gabriel N. Hortobagyi;Aman U. Buzdar;Frederick C. Ames.
Cancer Research (1986)

464 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing George R. Blumenschein

Gabriel N. Hortobagyi

Gabriel N. Hortobagyi

The University of Texas MD Anderson Cancer Center

Publications: 169

John V. Heymach

John V. Heymach

The University of Texas MD Anderson Cancer Center

Publications: 94

Ignacio I. Wistuba

Ignacio I. Wistuba

The University of Texas MD Anderson Cancer Center

Publications: 74

Robert L. Ferris

Robert L. Ferris

University of Pittsburgh

Publications: 73

Zhongxing Liao

Zhongxing Liao

The University of Texas MD Anderson Cancer Center

Publications: 73

Roy S. Herbst

Roy S. Herbst

Yale University

Publications: 71

Aman U. Buzdar

Aman U. Buzdar

The University of Texas at Austin

Publications: 68

Suresh S. Ramalingam

Suresh S. Ramalingam

Emory University

Publications: 65

Jordan U. Gutterman

Jordan U. Gutterman

The University of Texas MD Anderson Cancer Center

Publications: 60

Benjamin Besse

Benjamin Besse

Institut Gustave Roussy

Publications: 58

Martin Reck

Martin Reck

Autonomous University of Madrid

Publications: 57

Dirk De Ruysscher

Dirk De Ruysscher

Maastricht University

Publications: 57

Razelle Kurzrock

Razelle Kurzrock

Medical College of Wisconsin

Publications: 56

J. Jack Lee

J. Jack Lee

The University of Texas MD Anderson Cancer Center

Publications: 55

Lisa Licitra

Lisa Licitra

University of Milan

Publications: 54

Ming-Sound Tsao

Ming-Sound Tsao

Princess Margaret Cancer Centre

Publications: 51

Something went wrong. Please try again later.